| アブストラクト | INTRODUCTION: This analysis compared healthcare resource use (HCRU) and costs associated with incident organ damage in a cohort of adult patients with systemic lupus erythematosus (SLE). METHODS: Incident SLE cases were identified (Clinical Practice Research Datalink [CPRD] and Hospital Episode Statistics-linked healthcare databases; January 1, 2005-June 30, 2019). Annual incidence of 13 organ damage domains was calculated from SLE diagnosis through follow-up. Annualized HCRU and costs were compared between organ damage and non-organ damage patient groups using generalized estimating equations. RESULTS: A total of 936 patients met the inclusion criteria for SLE. Mean age was 48.0 (standard deviation [SD] 15.7) years and 88% were female. Over a median follow-up period of 4.3 (interquartile range [IQR] 1.9-7.0) years, 59% (315/533) had evidence of post-SLE diagnosis incident organ damage (>/= 1 type), which was greatest for musculoskeletal (146/819 [18%]), cardiovascular (149/842 [18%]), and skin (148/856 [17%]) domains. Patients with organ damage had greater resource use for all organ systems, excluding gonadal, versus those without it. Overall, mean (SD) annualized all-cause HCRU was greater in patients with organ damage versus those without it (inpatient, 1.0 versus 0.2; outpatient, 7.3 versus 3.5; accident and emergency, 0.5 versus 0.2 days; primary care contacts, 28.7 versus 16.5; prescription medications, 62.3 versus 22.9). Adjusted mean annualized all-cause costs were significantly greater in both post- and pre-organ damage index periods for patients with organ damage versus those without it (all P < 0.05, excluding gonadal). Overall organ damage was associated with significantly increased adjusted mean annualized per-patient cost ( pound4442 greater [P < 0.0001]) ranging between pound2709 and pound7150 greater depending on the organ damage type. CONCLUSION: Organ damage was associated with higher HCRU and healthcare costs, before and after SLE diagnosis. More effective SLE management may slow disease progression, prevent organ damage onset, improve clinical outcomes, and reduce healthcare costs. |
|---|
| ジャーナル名 | Rheumatology and therapy |
|---|
| Pubmed追加日 | 2023/7/4 |
|---|
| 投稿者 | Stirnadel-Farrant, Heide A; Golam, Sarowar M; Naisbett-Groet, Barbara; Gibson, Danny; Langham, Julia; Langham, Sue; Samnaliev, Mihail |
|---|
| 組織名 | BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.;Heide.Stirnadel-Farrant@astrazeneca.com.;Oncology Business Unit, AstraZeneca, AstraZeneca Academy House, 136 Hills Road,;Cambridge, CB2 8PA, UK. Heide.Stirnadel-Farrant@astrazeneca.com.;BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.;Health Economics, AstraZeneca, Cambridge, UK.;Epidemiology Group, Maverex Limited, Newcastle-Upon-Tyne, UK.;Health Economics Group, Maverex Limited, Newcastle-Upon-Tyne, UK.;Statistical Group, Maverex Limited, Newcastle-Upon-Tyne, UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37400683/ |
|---|
